NYT: Goldman Sachs caught in the middle of Valeant, Allergan takeover fight

Carly Helfand Goldman Sachs has a reputation for helping its clients ward off hostile takeover attempts. But since Allergan brought the firm on to defend against Valeant's unsolicited ...

EMA board agrees to approve revised trial data policy

Emily Mullin The management board of the European Medicines Agency (EMA) agreed on June 12 to approve a new policy that would require drug companies to share certain clinical trial ...

NIH gives Venter’s genomics institute $25M to decode infectious disease

Damian Garde NIH has signed on to give the J. Craig Venter Institute $ 25 million over 5 years to study infectious diseases including influenza and malaria, working to spotlight new ...

Could automating production solve India’s manufacturing problems?

Carly Helfand Some drugmakers–like Dr. Reddy's Laboratories–are wondering whether manufacturing troubles could be reduced by taking human workers out of the equation. FiercePharma ...

Sanofi CEO: No deals? No problem

Carly Helfand Pharma is riding an M&A deal wave like none the industry has ever seen, with companies looking to shed noncore businesses and bulk up in areas they want to focus on. ...

GW hits the FDA fast track with its cannabis-based epilepsy drug

Damian Garde The FDA has applied its fast-track designation to GW Pharmaceuticals' Epidiolex, a cannabinoid treatment for a rare form of epilepsy. FierceBiotech News

Alkermes sues Boston biotech startup for trademark infringement

Emily Mullin Startup Alkeus is being sued by Irish drugmaker Alkermes for trademark infringement. According to the Boston Business Journal, the 25-year-old Alkermes filed the lawsuit ...

With predators knocking, Shire needs to go on the hunt, analysts say

Carly Helfand They say the best defense is a good offense, and that just may be the case for Shire. Amid pharma's ongoing deal frenzy, the Dublin-based company–a prime target ...

Analysts: Shire must go shopping to stay independent

Damian Garde Rumors that Shire is preparing a 10-figure bid for NPS Pharma may have been overblown, but analysts say the Irish drugmaker should take a hard look at M&A if it wants ...

Persevering in Eastern Europe despite unrest, Stada eyes more deals

Tracy Staton Trouble in the Ukraine and Russia forced Germany's Stada to cut its earnings forecast two months ago. Now, Stada CEO Hartmut Retzlaff says the company hasn't gone ...

How to sell a statin? Pfizer and AstraZeneca have different ideas

Tracy Staton It's a tale of two statin drugs and their attempts to keep market share–or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay ...

Trevi, Complexa bag $38M in VC cash to hit the gas on R&D

Damian Garde Two biotech startups have hauled in a combined $ 38 million in Series B funding, pledging to advance their programs in inflammation and skin disease. FierceBiotech News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS